Search Results 101-110 of 16732 for CLL
-
... chronic lymphocytic leukemia (CLL) with 17p deletion. An increased rate of deaths and serious adverse events (SAEs) among participants with front-line CLL ...
-
Confirmed diagnosis of chronic lymphocytic leukemia (CLL). · Must have received at least two (2) prior therapy regimens. · Patients with Richter's transformation ...
-
Contact Dr. Slager about her research on the genetic basis of chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis, or about enrolling in a ...
-
... chronic lymphocytic leukemia (CLL). Most newly-diagnosed CLL patients have early-stage disease at the time of diagnosis and do not require treatment.
-
Venetoclax is FDA approved for the treatment of CLL and SLL. The drug combination of acalabrutinib, durvalumab, and venetoclax is experimental and isn't ...
-
All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...
-
... chronic lymphocytic leukemia (CLL) in comparison to age-matched healthy ... Venetoclax is FDA approved for the treatment of CLL and SLL. The drug ...
-
A Study Evaluating the Safety and Effectiveness of JCAR017 to Treat Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).
-
... CLL. Conditions treated · Chronic lymphocytic leukemia · Hairy cell leukemia · Hodgkin lymphoma · Non-Hodgkin's lymphoma · Procedures performed · Cancer ...
-
... chronic lymphocytic leukemia (CLL). It is composed of a patient survey (n=250), a physician survey (n=100), and a practice survey completed by each site ...